在膀癌中作为可向位的天然基因 justicidin A 诱导的细胞衰变
Kai-Hsun Chang1, Hsin-Chih Chen2, Ching-Ying Chen3
1Department of Human Development and Family Studies, National Taiwan Normal University, Taipei 10610, Taiwan.
Chemico-biological interactions
|September 5, 2025
概括
利格南 justicidin A (JA) 诱导线粒细胞衰变,这是一种降解受损线粒体的过程,在膀癌中表现为瘤抑制剂. 这种涉及BNIP3的机制可以增强化疗效率,克服药物耐药性.
科学领域:
- 线粒体生物学
- 癌症研究
- 自食
背景情况:
- 累积的功能障碍线粒体有助于癌症的发展.
- 线粒体的选择性降解,被假定具有瘤抑制功能.
- 在癌症治疗中, 识别诱导细胞衰变的自然化合物至关重要.
研究的目的:
- 作为潜在的菌诱导剂,研究基素A (JA).
- 为了阐明JA诱导的细胞衰减在HRAS突变膀癌中的作用.
- 探索JA与化疗的治疗潜力.
主要方法:
- 生物信息学分析以确定JA作为菌诱导剂.
- 使用HRAS突变的T24和野生型E7膀癌细胞进行基于细胞的测定.
- 对焦和电子显微镜可视化菌标志物 (LC3,HSP60,BNIP3).
- 对基因表达 (HIF-1α,BNIP3) 和蛋白质相互作用的分析.
- 在膀皮癌中对线粒细胞的患者数据分析
主要成果:
- 降低了T24细胞生长,改变了线粒体膜潜力,并诱导了自.
- JA治疗导致线粒体点数减少和LC3与HSP60在自囊中的同定位,证实了线粒体.
- 在HRAS突变细胞中,JA增加了HIF-1α和BNIP3的表达.
- 在T24细胞中增强了cisplatin和gemcitabine的细胞毒性.
- 膀癌组织中减少的线粒体基因表达和对西斯抗性细胞的减少表明瘤抑制作用.
结论:
- 在HRAS突变的膀癌细胞中,JA是BNIP3介导的强烈诱导剂.
- 在膀癌中,菌作用作为瘤抑制剂,可能通过使细胞对化疗敏感并克服耐药性.
- 作为治疗膀癌的一种有前途的药物,特别是在与常规化疗药物结合使用时.
相关概念视频
01:31The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K